Avoro News

Avoro Capital Updates

We are pleased to share industry insights and updates on Avoro and our portfolio companies. Please reach out if you would like to learn more.

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine

London, UK, 23 September 2024: Vicebio Ltd (“Vicebio”), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, today announces a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi. Vicebio is developing next-generation vaccines for respiratory viruses utilising its proprietary Molecular Clamp technology, discovered at The …

Read More

Avoro Ventures Adds Mark Chin as a Partner

NEW YORK–(BUSINESS WIRE)–Avoro Ventures, a global venture capital firm investing in life sciences, announced today that Mark Chin has joined the firm as a Partner, focused on its venture capital investment efforts. Mark has 15 years of healthcare experience across venture capital, strategy consulting, business and corporate development. Prior to joining Avoro Ventures, Mark was …

Read More

Hemab Therapeutics Announces $135M Series B Financing to Advance First Prophylactic Treatments for Underserved Bleeding and Thrombotic Disorders

Funding enables completion of ongoing Phase 1/2 study of bispecific antibody HMB-001 in Glanzmann Thrombasthenia, initiation of pivotal studies, start and conclusion of Phase 1/2 study of HMB-VWF in von Willebrand Disease, as well as future pipeline evolution. COPENHAGEN, DENMARK and BOSTON, MASS., US – February 21, 2023 Hemab Therapeutics, a clinical-stage biotechnology company developing …

Read More

Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing

LOS ANGELES, Sept. 22, 2022 /PRNewswire/ — Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced it has entered into a securities purchase agreement with a new accredited investor and certain existing investors to issue and sell an aggregate of 3,373,526 shares of …

Read More

LATEST
202420232022202120202018201720152014